|
1）Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease （CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009; 15: 171-81
|
|
|
|
2）Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007; 115: 1643-55
|
|
|
|
|
|
3）Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in （Young) Adults. Circulation. 1995; 92: 785-9
|
|
|
|
|
|
4）Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013; 99: 1800-11
|
|
|
|
|
|
5）Blankenburg R, Hackert K, Wurster S, et al. β-Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations. Circ Res. 2014; 115: 227-37
|
|
|
|
|
|
6）Debold EP, Schmitt JP, Patlak JB, et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol. 2007; 293: H284-91
|
|
|
|
|
|
7）Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996; 272: 731-4
|
|
|
|
|
|
8）Palmer BM, Fishbaugher DE, Schmitt JP, et al. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol. 2004; 287: H91-9
|
|
|
|
|
|
9）Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest. 2010; 120: 3520-9
|
|
|
|
|
|
10）Fatkin D, McConnell BK, Mudd JO, et al. An abnormal Ca（2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. The Journal of clinical investigation. 2000; 106: 1351-9
|
|
|
|
|
|
11）Konno T, Chen D, Wang L, et al. Heterogeneous myocyte enhancer factor-2 （Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy. Pro Nat Acad Sci U S A. 2010; 107: 18097-102
|
|
|
|
|
|
12）Jones WK, Grupp IL, Doetschman T, et al. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest. 1996; 98: 1906-17
|
|
|
|
|
|
13）Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus （AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21: 704-12
|
|
|
|
|
|
14）Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011; 12: 341-55
|
|
|
|
|
|
15）Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998; 351: 1702-3
|
|
|
|
|
|
16）Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365: 2357-65
|
|
|
|
|
|
17）Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med. 2011; 3: 92ra64
|
|
|
|
|
|
18）Jiang J, Wakimoto H, Seidman JG, et al. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science. 2013; 342: 111-4
|
|
|
|
|
|
19）Bish LT, Morine K, Sleeper MM, et al. Adeno-associated virus （AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008; 19: 1359-68
|
|
|
|
|
|
20）Tripathi S, Schultz I, Becker E, et al. Unequal allelic expression of wild-type and mutated beta-myosin in familial hypertrophic cardiomyopathy. Basic Res Cardiol. 2011; 106: 1041-55
|
|
|
|
|
|
21）Denegri M, Bongianino R, Lodola F, et al. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. Circulation. 2014; 129: 2673-81
|
|
|
|
|
|
22）Katz MG, Fargnoli AS, Swain JD, et al. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery （MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg. 2012; 143: 720-6. e3
|
|
|
|
|
|
23）White JD, Thesier DM, Swain JB, et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther. 2011; 18: 546-52
|
|
|
|
|